Gathering feedback on severe malaria and its treatment

Severe malaria is a life-threatening condition. It may ensue rapidly if a bout of acute uncomplicated malaria is not promptly treated. By sharing their experiences on severe malaria, all stakeholders participate in a better understanding of the appropriate treatment for all patients.   

The Severe Malaria Observatory 

To help share knowledge, experiences and guidance on severe malaria, MMV launched the Severe Malaria Observatory (SMO) in May 2017.  

The SMO was created to shine a light on severe malaria. It serves as a repository of information about this fatal disease and is consulted by over 8,000 users each month. 

Partners are encouraged to share this platform widely and motivate members of the community to also share their knowledge and experiences via SMO. 


  • Past and current partners: 

    Centers for Disease Control and Prevention (CDC); CHAI; IPCA Laboratories; École de SantéPublique University of Kinshasa; Guilin Pharma, a Fosun Pharma company; Kenya National Malaria Control Program; Malaria Consortium; Malaria No More; MSF; National Malaria Control Programme Ghana; Nigeria National Malaria Control Programme; Swiss Tropical and Public Health Institute; The Global Fund to Fight AIDS Tuberculosis and Malaria; UNICEF; Unitaid; University of Oxford, WHO GMP.